(The Transmitter) – A reanalysis of the data revealed errors and failed to replicate the results.

The largest study to date of leucovorin’s effectiveness for treating autism traits has been retracted because of data inconsistencies and statistical issues, according to a notice posted last week by the European Journal of Pediatrics. 

The study included 77 autistic children and is one of only five randomized clinical trials that have tested leucovorin, also known as folinic acid, in autistic people. (Read More)